Through its wholly-owned subsidiary, Growblox Life Sciences, LLC, GB Sciences has filed three patent applications containing formulations to tackle the following conditions.
Patient Groups
Neurological Disorders
Our first patent application contains cannabis-based complex mixtures designed to treat Parkinson’s Disease, Lewy Body Dementia, Huntington’s Disease, Dementia and Alzheimer’s Disease. Overall, there is a lack of good therapies for these patients. As people are living longer, the numbers of these undertreated patients are increasing. Fortunately, there is a common mechanism underlying these neurological disorders that our therapies address, and we are eager to continue the development of these medications.
Inflammatory Disorders
Our second patent application contains cannabis-based complex mixtures for the treatment of a variety of inflammatory disorders, which are increasingly prevalent in our society and add more than $300 billion dollars to the healthcare burden in the US. Some of these disorders included in our patent application are Osteoarthritis, Rheumatoid arthritis, Crohn’s disease, Inflammatory Bowel Disease (IBD), allergic asthma, COPD/asthma in adults, eczema, and dermatitis. Our therapies are designed to help patients in all of these groups by focusing on commonalities in inflammatory pathways that lead to significant pain and suffering for these patients.
Cardiovascular Disease
Our third patent describes the use of our myrcene-containing complex mixtures for the treatment of heart disease. Heart disease remains the number one cause of death in the US, and there have been no novel formulations on the market for heart disease in almost twenty years. In the US, the heart disease market is $316 billion dollars. Our formulations target the TRPV1 receptor that is protected under the approved patent that we licensed from Makai Biotechnology in December of 2016.
Chronic and Neuropathic Pain
Our third patent application also addresses patients with chronic and neuropathic pain. Recently, many patients and their physicians have been expressing their dissatisfaction with currently-available pain medications. Growing public and government concerns regarding opioid abuse, make novel pain treatments a promising field of research and development. Our novel pain formulations are also substantially free of delta-9 tetrahydrocannabinol (“THC”), which minimizes their potential for abuse. Pain represents an estimated health burden of between $560 and $650 billion dollars for chronic pain and between $17 and $20 billion dollars for immunological/neuropathic pain in the US alone.
